Alzheimer's Research: Unlocking the Mystery of a Complex Disease
The quest for effective Alzheimer's disease (AD) treatments is a captivating journey, as highlighted at the Alzheimer Congress 2026. While antiamyloid immunotherapies remain a cornerstone, the therapeutic landscape is evolving with mixed results.
Real-World Insights:
Mathieu Ceccaldi and Davide Angioni presented a comprehensive review of recent advancements. Real-world data from various countries reveal consistent cognitive and functional improvements in AD patients. Interestingly, amyloid-related imaging abnormalities are less frequent in clinical practice than in pivotal trials.
Donanemab's Promise:
The TRAILBLAZER-ALZ 2 study extended its donanemab trial, showing sustained benefits. Cognitive decline curves widened between donanemab and placebo groups from 18 to 36 months. Amyloid clearance was maintained below the threshold during the extension phase. And here's the intriguing part: patients initially on placebo experienced slower cognitive decline after switching to donanemab.
Trontinemab's Rise:
Trontinemab, a promising antiamyloid monoclonal antibody, is making waves. Updated data from the Brainshuttle AD study demonstrated impressive amyloid clearance at 28 weeks, with 92% of high-dose patients falling below the positivity threshold. This was accompanied by reduced cerebrospinal fluid (CSF) biomarkers associated with amyloid and tau pathologies. But here's where it gets controversial—preliminary analyses hinted at less cognitive decline, yet hemorrhagic amyloid-related imaging abnormalities occurred in a small percentage of participants.
Semaglutide's Setback:
Despite its success in obesity and type 2 diabetes, semaglutide failed to show cognitive benefits in AD. The evoke and evoke+ trials, involving 1840 early-stage AD patients, did not demonstrate cognitive improvement at 18 months. However, CSF biomarker reductions were observed, including tau proteins and neuroinflammation markers.
Tau-Targeted Therapies:
Bepranemab, a novel humanized antibody, was tested in the TOGETHER trial. Although it didn't reduce cognitive decline, it's the first antibody to decrease tau protein accumulation in AD patients. An open-label extension showed a lower tau burden in treated patients compared to those initially on placebo. But the story doesn't end there—patients who switched from placebo to bepranemab experienced slower tau accumulation.
Etalanetug's Potential:
Etalanetug, another anti-tau antibody, showed promise in a phase 1b/2a study for autosomal dominant AD. It reduced tau biomarkers in both CSF and plasma, with substantial reductions at 2 years. This candidate warrants further monitoring, according to Angioni.
The Alzheimer's research field is filled with both triumphs and setbacks, leaving room for ongoing exploration and debate. What are your thoughts on the latest developments? Do you think these findings will shape the future of AD treatment?
